NASDAQ · PVLA
Palvella Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PVLA: Nov 05, 2026
Palvella Therapeutics, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.65. The reported EPS for the same quarter last year was $-1.03.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.65 | $-1.05 | $-1.98 | 5 |
| Dec 2026 | $-1.83 | $-1.21 | $-2.17 | 5 |
| Mar 2027 | $-2.12 | $-1.70 | $-2.40 | 3 |
| Jun 2027 | $-2.26 | $-1.81 | $-2.59 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · BNK Invest · The Motley Fool- RTTNews · Oct 28, 8:51 AM EDTPalvella Gets FDA Priority Review For QTORIN Rapamycin; Decision Expected In February 2027; Stock Up(RTTNews) – Palvella Therapeutics Inc. (PVLA) announced that the U.S. FDA has accepted its NDA for QTORIN 3.9% rapamycin anhydrous gel and granted it Priority Review for treating microcystic lymphatic malformations (LMs). The FDA has set a target action date of February 28, 2027.
- MarketBeat · Oct 25, 2:03 AM EDTPalvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline ExpandsPalvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company ha
- BNK Invest · Oct 2, 4:34 PM EDTPalvella Therapeutics is Now Oversold (PVLA)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Sep 28, 7:48 AM EDTPalvella Receives Additional FDA Funding For QTORIN Rapamycin In Lymphatic Malformations(RTTNews) – Palvella Therapeutics, Inc. (PVLA) announced that it received a third year of grant funding from the FDA Office of Orphan Products Development to support the Phase 3 SELVA trial and ongoing open-label extension study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapa
- RTTNews · Aug 31, 11:31 AM EDTPalvella Completes Rolling NDA For QTORIN Rapamycin In Microcystic Lymphatic Malformatios(RTTNews) – Palvella Therapeutics, Inc. (PVLA) announced that it has completed the rolling submission of its NDA to the U.S. FDA for QTORIN 3.9% rapamycin anhydrous gel.
- MarketBeat · Aug 16, 12:01 PM EDTPalvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline ExpandsPalvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymph
- The Motley Fool · Aug 11, 1:16 PM EDTPalvella (PVLA) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 4, 1:04 PM EDTPalvella Therapeutics Q2 Earnings Call HighlightsPalvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027. The
- RTTNews · Jul 21, 11:20 PM EDTTop Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing(RTTNews) – Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as investors look ahead to key SGT-610 Phase 3
- BNK Invest · Jul 15, 3:21 PM EDTNotable Wednesday Option Activity: RDDT, PVLA, WORAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Reddit Inc (Symbol: RDDT), where a total of 27,612 contracts have traded so far, representing approximately 2.8 million underlying shares. That amounts to about 66.3% of
- The Motley Fool · Jun 27, 12:31 PM EDTWhat to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share.
- RTTNews · Jun 24, 10:04 AM EDT6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More(RTTNews) – "The market is a device for transferring money from the impatient to the patient." – Warren Buffett.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Palvella Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.